BE903128A - Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant - Google Patents

Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant

Info

Publication number
BE903128A
BE903128A BE0/215506A BE215506A BE903128A BE 903128 A BE903128 A BE 903128A BE 0/215506 A BE0/215506 A BE 0/215506A BE 215506 A BE215506 A BE 215506A BE 903128 A BE903128 A BE 903128A
Authority
BE
Belgium
Prior art keywords
group
preparation
agents containing
benzimidazole derivatives
hydrogen atom
Prior art date
Application number
BE0/215506A
Other languages
English (en)
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP59182400A external-priority patent/JPS6160660A/ja
Priority claimed from JP60061194A external-priority patent/JPH068283B2/ja
Priority claimed from JP60061195A external-priority patent/JPH0764826B2/ja
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of BE903128A publication Critical patent/BE903128A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D235/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Des dérives de benzimodazole de formule (I) dans laquelle R1 représente un atome d'hydrogène, un groupe alkyle en C1-C8, un groupe cycloalkyle, un groupe phényle ou un groupe aralkyle, R2 représente un atome d'hydrogène ou un groupe alkyle en C1-C8, ou encore R1 et R2 forment un noyau ensemble avec l'atome d'azote adjacent, tandis que R3 et R4 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe trifluorométhyle, un groupe alkyle inférieur, un groupe alcoxy inférieur, un groupe alcoxy inférieur-carbonyle ou un groupe amino, ces dérivés étant efficaces contre les ulcères.
BE0/215506A 1984-08-31 1985-08-27 Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant BE903128A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP59182400A JPS6160660A (ja) 1984-08-31 1984-08-31 ベンズイミダゾ−ル誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
JP60061194A JPH068283B2 (ja) 1985-03-26 1985-03-26 ベンズイミダゾ−ル誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
JP60061195A JPH0764826B2 (ja) 1985-03-26 1985-03-26 ベンズイミダゾール誘導体

Publications (1)

Publication Number Publication Date
BE903128A true BE903128A (fr) 1985-12-16

Family

ID=27297422

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/215506A BE903128A (fr) 1984-08-31 1985-08-27 Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant

Country Status (14)

Country Link
KR (1) KR920004936B1 (fr)
AR (1) AR242195A1 (fr)
AU (3) AU4640985A (fr)
BE (1) BE903128A (fr)
BR (1) BR8504252A (fr)
CH (1) CH665417A5 (fr)
DE (1) DE3531487C2 (fr)
ES (1) ES8703142A1 (fr)
FR (1) FR2569691B1 (fr)
GB (1) GB2163747B (fr)
IT (1) IT1189601B (fr)
MX (1) MX159807A (fr)
NL (1) NL8502384A (fr)
SE (1) SE500669C2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687775A (en) * 1986-07-17 1987-08-18 G. D. Searle & Co. 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles
US4721718A (en) * 1986-08-18 1988-01-26 G. D. Searle & Co. 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers
US4772619A (en) * 1986-07-17 1988-09-20 G. D. Searle & Co. [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8417194D0 (en) * 1984-07-05 1984-08-08 Boots Co Plc Therapeutic agents
DE3585252D1 (de) 1984-07-06 1992-03-05 Fisons Plc Benzimidazole, und verfahren zu deren herstellung, deren formulierung und verwendung als magensaeuresekretionshemmende verbindungen.
GB2161160B (en) * 1984-07-06 1989-05-24 Fisons Plc Heterocyclic sulphinyl compounds
US5869513A (en) * 1985-05-24 1999-02-09 G. D. Searle & Co. 2- (1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines
EP0204215B1 (fr) * 1985-05-24 1993-08-11 G.D. Searle & Co. [(1H-benzimidazol-yl-2-sulfonyl)méthyl]-2-benzèneamines
US4824856A (en) * 1985-08-14 1989-04-25 Nippon Chemiphar Co., Ltd. Method of protecting gastrointestinal tract
EP0232399A1 (fr) * 1985-08-21 1987-08-19 Byk Gulden Lomberg Chemische Fabrik GmbH Nouvelles amines, leur procede de fabrication, leur utilisation, et medicaments les contenant
AR243167A1 (es) 1985-08-24 1993-07-30 Hoechst Ag Procedimiento para la preparacion de toluidinas sustituidas.
AU619444B2 (en) * 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
EP0251536A1 (fr) * 1986-06-24 1988-01-07 FISONS plc Benzimidazoles, leur préparation, formulation et utilisation comme inhibiteurs de sécrétion d'acide gastrique
DE3639926A1 (de) * 1986-11-22 1988-06-01 Hoechst Ag Substituierte thienoimidazoltoluidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
IT1222412B (it) * 1987-07-31 1990-09-05 Chiesi Farma Spa Tiometil e sulfinil metil derivati ad azione antisecretiva acida gastrica,loro procedimento di preparazione e composizioni farmaceutiche che li contengono
JP2614756B2 (ja) * 1988-08-10 1997-05-28 日本ケミファ株式会社 イミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
JPH06298611A (ja) * 1993-04-16 1994-10-25 Nippon Chemiphar Co Ltd 抗菌剤
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
DK1092434T3 (da) * 1995-09-21 2004-07-26 Pharma Pass Ii Llc Hidtil ukendt sammensætning indeholdende lansoprazol og fremgangsmåde til fremstilling deraf
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
ATE281178T1 (de) 1997-07-25 2004-11-15 Altana Pharma Ag Protonenpumpenhemmer als kombinationstherapeutika mit antibakterielle wirkenden substanzen
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
AU772726B2 (en) 1998-08-12 2004-05-06 Takeda Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
WO2000027841A1 (fr) * 1998-11-06 2000-05-18 Dong-A Pharmaceutical Co., Ltd. Procede de preparation de derives de sulfure
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
PT1187601E (pt) 1999-06-07 2005-11-30 Altana Pharma Ag Nova forma de preparacao e a administracao compreendendo um inibidor da bomba de protoes instavel em meio acido
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
CA2480824A1 (fr) 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
CA2529984C (fr) 2003-06-26 2012-09-25 Isa Odidi Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
EP1708684A2 (fr) 2003-09-26 2006-10-11 Alza Corporation Enrobage de medicaments a charge medicamenteuse elevee et procedes de fabrication
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
US9561188B2 (en) 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
US9205094B2 (en) 2006-12-22 2015-12-08 Ironwood Pharmaceuticals, Inc. Compositions comprising bile acid sequestrants for treating esophageal disorders
MX2011002515A (es) 2008-09-09 2011-04-07 Astrazeneca Ab Metodo de administracion de una composicion farmaceutica a un paciente que lo necesita.
MX2011013467A (es) 2009-06-25 2012-02-13 Astrazeneca Ab Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine).
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080501A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2601947A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
CN108057028A (zh) 2013-01-15 2018-05-22 铁木医药有限公司 片剂形式的肠溶包衣的胃内滞留口服剂型及其应用和药物组合物
EP2801565B1 (fr) 2013-05-06 2015-07-22 King Saud University Composés destinés à être utilisés en tant qu'agent antiulcéreux et/ou agent anti-helicobacter pylori et leurs compositions pharmaceutiques
US20180015118A1 (en) 2015-02-03 2018-01-18 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
DE3585252D1 (de) * 1984-07-06 1992-03-05 Fisons Plc Benzimidazole, und verfahren zu deren herstellung, deren formulierung und verwendung als magensaeuresekretionshemmende verbindungen.

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687775A (en) * 1986-07-17 1987-08-18 G. D. Searle & Co. 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles
US4772619A (en) * 1986-07-17 1988-09-20 G. D. Searle & Co. [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines
US4721718A (en) * 1986-08-18 1988-01-26 G. D. Searle & Co. 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers

Also Published As

Publication number Publication date
IT8567743A0 (it) 1985-08-30
DE3531487A1 (de) 1986-03-13
NL8502384A (nl) 1986-03-17
AR242195A1 (es) 1993-03-31
ES546445A0 (es) 1986-11-16
SE500669C2 (sv) 1994-08-08
CH665417A5 (fr) 1988-05-13
FR2569691A1 (fr) 1986-03-07
AU4127189A (en) 1989-12-21
GB2163747A (en) 1986-03-05
AU2975092A (en) 1993-01-28
GB2163747B (en) 1989-02-08
IT1189601B (it) 1988-02-04
AU647978B2 (en) 1994-03-31
SE8504048L (sv) 1986-03-01
ES8703142A1 (es) 1986-11-16
SE8504048D0 (sv) 1985-08-30
GB8521493D0 (en) 1985-10-02
AU4640985A (en) 1986-03-06
DE3531487C2 (de) 1995-08-17
FR2569691B1 (fr) 1989-08-04
KR860001793A (ko) 1986-03-22
KR920004936B1 (ko) 1992-06-22
MX159807A (es) 1989-08-31
BR8504252A (pt) 1986-06-17

Similar Documents

Publication Publication Date Title
BE903128A (fr) Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant
DE3677452D1 (de) Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
BE1002211A4 (fr) (pentamethyl-1,2,2,6,6 piperidyl-4-amino)-triazines, leur application comme stabilisants de matieres organiques, et compositions qui en contiennent.
BE903778A (fr) Derives d'indoles.
BE900275A (fr) Azetidinones.
BE901987A (fr) Derives d'alcanolamines et inhibiteurs de l'agregation des plaquettes en contenant comme principe actif.
HUT37751A (en) Process for production of new, substituated prrolidinons
DE69229057D1 (de) 1-(arylalkyl-aminoalkyl) imidazolderivate, herstellungs verfahren und verwendung als therapeutische mittel
BE904641A (fr) 5-pyrimidine-carboxamides et traitement de la leucemie et des tumeurs avec ces derniers.
BE902710A (fr) Procede stereospecifique pour la preparation d'azetidinones.
BE900183A (fr) N-dichloracetyl-glycinamides substituees sur n et eventuellement sur n' et leur utilisation comme antidotes dans les herbicides.
BE1002181A3 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances.
BE905340A (fr) Derives du methylene-dioxy-phenanthrene et du stilbene, procede pour leur preparation et medicaments les contenant.
BE1003158A5 (fr) Preparation de composes heterocycliques.
BE902150A (fr) Derives de la 1h, 7h-pyrazolo (1,5-a) pyrimidine-7-one et procede pour leur preparation.
BE900718A (fr) Nouveaux derives du carbapeneme, leur preparation et leur utilisation comme medicaments.
BE904409Q (fr) Nouveaux colorants cupriferes et leur preparation.
BE905297A (fr) Derives heterocycliques.
BE1003314A3 (fr) Procede de dedoublement d'intermediaires interessants dans la preparation de diltiazem.
BE904016A (fr) Nouveaux derives naphtaleniques du benzonorbornene, leur procede de preparation et compositions medicamenteuse et cosmetique les contenant
BE901072A (fr) Procede de decarbonylation selective.
BE900882A (fr) Derives de 2h-azeto(2,1-a)-isoquinoleine, procede pour les preparer et compositions pharmaceutiques les contenant.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: NIPPON CHEMIPHAR CO. LTD

Effective date: 20000831